Image
PTC Therapeutics have shared the clinical data presented at the International SMA Europe Conference in France.
The study showed improvement in muscle function in people with SMA type 2 and 3 when treated with risdiplam over a period of 12 months. Children aged 2-5 years, showed improvement compared to those not receiving the drug. In people older than 5, the progression of the condition stabilised.
The company will be presenting the data in a conference call for investors at 1pm today. It can be accessed by dialing (973) 935-8152 five minutes before the start of the call and entering the passcode 7757508.
For more information, read PTC’s press release.
If you have any research questions, please contact our Research Line on research@musculardystrophyuk.org